{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T21:03:24Z","timestamp":1768511004693,"version":"3.49.0"},"posted":{"date-parts":[[2024,5,17]]},"group-title":"Cancer Biology","reference-count":59,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,5,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>\n                    Medulloblastoma (MB) is the most malignant childhood brain cancer. Group 3 MB subtype accounts for about 25% of MB diagnoses and is associated with the most unfavorable outcomes. Herein, we report that more than half of group 3 MB tumors express melanoma antigens (MAGEs), which are potential prognostic and therapeutic markers. MAGEs are tumor antigens, expressed in several types of adult cancers and associated with poorer prognosis and therapy resistance; however, their expression in pediatric cancers is mostly unknown. The aim of this study was to determine whether\n                    <jats:italic>MAGEs<\/jats:italic>\n                    are activated in pediatric MB.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>\n                    To determine\n                    <jats:italic>MAGE<\/jats:italic>\n                    frequency in pediatric MB, we obtained formalin-fixed paraffin-embedded tissue (FFPE) samples of 34 patients, collected between 2008 \u2013 2015, from the Children\u2019s Medical Center Dallas pathology archives and applied our validated reverse transcription quantitative PCR (RT-qPCR) assay to measure the relative expression of 23\n                    <jats:italic>MAGE<\/jats:italic>\n                    cancer-testis antigen genes. To validate our data, we analyzed several published datasets from pediatric MB patients and patient-derived orthotopic xenografts, totaling 860 patients. We then examined how\n                    <jats:italic>MAGE<\/jats:italic>\n                    expression affects the growth and oncogenic potential of medulloblastoma cells by CRISPR-Cas9- and siRNA-mediated gene depletion.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>\n                    Our RT-qPCR analysis suggested that\n                    <jats:italic>MAGEs<\/jats:italic>\n                    were expressed in group 3\/4 medulloblastoma. Further mining of bulk and single-cell RNA-sequencing datasets confirmed that 50-75% of group 3 tumors activate a subset of\n                    <jats:italic>MAGE<\/jats:italic>\n                    genes. Depletion of MAGEAs, B2, and Cs alter MB cell survival, viability, and clonogenic growth due to decreased proliferation and increased apoptosis.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These results indicate that targeting MAGEs in medulloblastoma may be a potential therapeutic option for group 3 medulloblastomas.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Key Points<\/jats:title>\n                  <jats:list list-type=\"bullet\">\n                    <jats:list-item>\n                      <jats:p>\n                        Several Type I\n                        <jats:italic>MAGE<\/jats:italic>\n                        CTAs are expressed in &gt;60% of group 3 MBs.\n                      <\/jats:p>\n                    <\/jats:list-item>\n                    <jats:list-item>\n                      <jats:p>Type I MAGEs affect MB cell proliferation and apoptosis.<\/jats:p>\n                    <\/jats:list-item>\n                    <jats:list-item>\n                      <jats:p>\n                        <jats:italic>MAGEs<\/jats:italic>\n                        are potential biomarkers and therapeutic targets for group 3 MBs.\n                      <\/jats:p>\n                    <\/jats:list-item>\n                  <\/jats:list>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Importance of the Study<\/jats:title>\n                  <jats:p>\n                    This study is the first comprehensive analysis of all Type I\n                    <jats:italic>MAGE<\/jats:italic>\n                    CTAs (\n                    <jats:italic>MAGEA<\/jats:italic>\n                    ,\n                    <jats:italic>-B<\/jats:italic>\n                    , and\n                    <jats:italic>-C<\/jats:italic>\n                    subfamily members) in pediatric MBs. Our results show that more than 60% of group 3 MBs express\n                    <jats:italic>MAGE<\/jats:italic>\n                    genes, which are required for the viability and growth of cells in which they are expressed. Collectively, these data provide novel insights into the antigen landscape of pediatric MBs. The activation of\n                    <jats:italic>MAGE<\/jats:italic>\n                    genes in group 3 MBs presents potential stratifying and therapeutic options.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Abstract Figure<\/jats:title>\n                  <jats:fig id=\"ufig1\" position=\"float\" orientation=\"portrait\" fig-type=\"figure\">\n                    <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"594201v1_ufig1\" position=\"float\" orientation=\"portrait\"\/>\n                  <\/jats:fig>\n                <\/jats:sec>","DOI":"10.1101\/2024.05.14.594201","type":"posted-content","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:55:15Z","timestamp":1715993715000},"source":"Crossref","is-referenced-by-count":0,"title":["Melanoma antigens in pediatric medulloblastoma contribute to tumor heterogeneity and species-specificity of group 3 tumors"],"prefix":"10.64898","author":[{"given":"Rebecca R.J.","family":"Collins","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca R. Florke","family":"Gee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Camila Hoyos","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sima","family":"Tozandehjani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara","family":"Bayat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Breznik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel T.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon P.","family":"Connelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shondra M.","family":"Pruett-Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine F.","family":"Roussel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6888-7902","authenticated-orcid":false,"given":"Dinesh","family":"Rakheja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather S.","family":"Tillman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick Ryan","family":"Potts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1928-7745","authenticated-orcid":false,"given":"Klementina","family":"Fon Tacer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024052113000625000_2024.05.14.594201v1.1","doi-asserted-by":"publisher","DOI":"10.2147\/JMDH.S167808"},{"issue":"1","key":"2024052113000625000_2024.05.14.594201v1.2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-019-0063-6","article-title":"Medulloblastoma","volume":"5","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2024052113000625000_2024.05.14.594201v1.3","doi-asserted-by":"publisher","DOI":"10.3171\/2019.5.PEDS18381"},{"key":"2024052113000625000_2024.05.14.594201v1.4","doi-asserted-by":"crossref","unstructured":"Casciati A , Tanori M , Manczak R , Saada S , Tanno B , Giardullo P , et al. Human Medulloblastoma Cell Lines: Investigating on Cancer Stem Cell-Like Phenotype. Cancers (Basel). 2020;12(1).","DOI":"10.3390\/cancers12010226"},{"key":"2024052113000625000_2024.05.14.594201v1.5","doi-asserted-by":"crossref","unstructured":"Liu KW , Pajtler KW , Worst BC , Pfister SM , Wechsler-Reya RJ . Molecular mechanisms and therapeutic targets in pediatric brain tumors. Sci Signal. 2017;10(470).","DOI":"10.1126\/scisignal.aaf7593"},{"key":"2024052113000625000_2024.05.14.594201v1.6","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106"},{"key":"2024052113000625000_2024.05.14.594201v1.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111162"},{"key":"2024052113000625000_2024.05.14.594201v1.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1434-6"},{"issue":"7929","key":"2024052113000625000_2024.05.14.594201v1.9","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/s41586-022-05208-9","article-title":"Unified rhombic lip origins of group 3 and group 4 medulloblastoma","volume":"609","year":"2022","journal-title":"Nature"},{"key":"2024052113000625000_2024.05.14.594201v1.10","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-011-0922-z"},{"key":"2024052113000625000_2024.05.14.594201v1.11","doi-asserted-by":"publisher","DOI":"10.1038\/nature22973"},{"key":"2024052113000625000_2024.05.14.594201v1.12","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-012-0958-8"},{"key":"2024052113000625000_2024.05.14.594201v1.13","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3410"},{"key":"2024052113000625000_2024.05.14.594201v1.14","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0692"},{"key":"2024052113000625000_2024.05.14.594201v1.15","doi-asserted-by":"crossref","first-page":"718030","DOI":"10.3389\/fonc.2021.718030","article-title":"T-Cell Immunotherapy for Pediatric High-Grade Gliomas: New Insights to Overcoming Therapeutic Challenges","volume":"11","year":"2021","journal-title":"Front Oncol"},{"key":"2024052113000625000_2024.05.14.594201v1.16","doi-asserted-by":"crossref","unstructured":"Abbott RC , Cross RS , Jenkins MR . Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies. Int J Mol Sci. 2020;21(2).","DOI":"10.3390\/ijms21020515"},{"issue":"1","key":"2024052113000625000_2024.05.14.594201v1.17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2024052113000625000_2024.05.14.594201v1.18","doi-asserted-by":"publisher","DOI":"10.1038\/nature12477"},{"issue":"10","key":"2024052113000625000_2024.05.14.594201v1.19","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.trecan.2018.08.005","article-title":"Emerging Contributions of Cancer\/Testis Antigens to Neoplastic Behaviors","volume":"4","year":"2018","journal-title":"Trends Cancer"},{"key":"2024052113000625000_2024.05.14.594201v1.20","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.REV120.008029"},{"key":"2024052113000625000_2024.05.14.594201v1.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2015.08.002"},{"key":"2024052113000625000_2024.05.14.594201v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2017.03.005"},{"key":"2024052113000625000_2024.05.14.594201v1.23","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aav4832"},{"key":"2024052113000625000_2024.05.14.594201v1.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.01.034"},{"key":"2024052113000625000_2024.05.14.594201v1.25","doi-asserted-by":"crossref","unstructured":"Alsalloum A , Shevchenko JA , Sennikov S . The Melanoma-Associated Antigen Family A (MAGE-A): A Promising Target for Cancer Immunotherapy? Cancers (Basel). 2023;15(6).","DOI":"10.3390\/cancers15061779"},{"key":"2024052113000625000_2024.05.14.594201v1.26","doi-asserted-by":"publisher","DOI":"10.3171\/PED\/2008\/1\/4\/305"},{"issue":"2","key":"2024052113000625000_2024.05.14.594201v1.27","first-page":"335","article-title":"Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers","volume":"5","year":"1999","journal-title":"Clin Cancer Res"},{"key":"2024052113000625000_2024.05.14.594201v1.28","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2017.016"},{"key":"2024052113000625000_2024.05.14.594201v1.29","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-015-0843-6"},{"key":"2024052113000625000_2024.05.14.594201v1.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2020.06.037"},{"key":"2024052113000625000_2024.05.14.594201v1.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2010.08.029"},{"key":"2024052113000625000_2024.05.14.594201v1.32","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now247"},{"key":"2024052113000625000_2024.05.14.594201v1.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.05.005"},{"issue":"2","key":"2024052113000625000_2024.05.14.594201v1.34","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/neuonc\/noab135","article-title":"Neoplastic and immune single-cell transcriptomics define subgroup-specific intra-tumoral heterogeneity of childhood medulloblastoma","volume":"24","year":"2022","journal-title":"Neuro Oncol"},{"key":"2024052113000625000_2024.05.14.594201v1.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.03.002"},{"key":"2024052113000625000_2024.05.14.594201v1.36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.4324"},{"key":"2024052113000625000_2024.05.14.594201v1.37","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-020-02171-5"},{"key":"2024052113000625000_2024.05.14.594201v1.38","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-380916-2.00008-5"},{"key":"2024052113000625000_2024.05.14.594201v1.39","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1158-7"},{"key":"2024052113000625000_2024.05.14.594201v1.40","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax7526"},{"issue":"3","key":"2024052113000625000_2024.05.14.594201v1.41","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/bpa.12803","article-title":"Modeling pediatric medulloblastoma","volume":"30","year":"2020","journal-title":"Brain Pathol"},{"key":"2024052113000625000_2024.05.14.594201v1.42","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.5665"},{"issue":"2","key":"2024052113000625000_2024.05.14.594201v1.43","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s13402-015-0261-5","article-title":"Melanoma associated antigen (MAGE)-A3 promotes cell proliferation and chemotherapeutic drug resistance in gastric cancer","volume":"39","year":"2016","journal-title":"Cell Oncol (Dordr"},{"key":"2024052113000625000_2024.05.14.594201v1.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2019.12.022"},{"key":"2024052113000625000_2024.05.14.594201v1.45","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7601218"},{"key":"2024052113000625000_2024.05.14.594201v1.46","doi-asserted-by":"publisher","DOI":"10.1042\/BCJ20160616"},{"key":"2024052113000625000_2024.05.14.594201v1.47","first-page":"7","article-title":"Cancer-testis (CT) antigen expression in medulloblastoma","volume":"8","year":"2008","journal-title":"Cancer Immun"},{"key":"2024052113000625000_2024.05.14.594201v1.48","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-008-9577-6"},{"issue":"3","key":"2024052113000625000_2024.05.14.594201v1.49","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bpa.12804","article-title":"Medulloblastoma genomics in the modern molecular era","volume":"30","year":"2020","journal-title":"Brain Pathol"},{"key":"2024052113000625000_2024.05.14.594201v1.50","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30532-1"},{"issue":"5","key":"2024052113000625000_2024.05.14.594201v1.51","doi-asserted-by":"crossref","first-page":"e0178370","DOI":"10.1371\/journal.pone.0178370","article-title":"Functional interaction between co-expressed MAGE-A proteins","volume":"12","year":"2017","journal-title":"PLoS One"},{"issue":"7","key":"2024052113000625000_2024.05.14.594201v1.52","first-page":"2778","article-title":"Overexpression of MAGE\/GAGE genes in paclitaxel\/doxorubicin-resistant human cancer cell lines","volume":"9","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2024052113000625000_2024.05.14.594201v1.53","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0510834103"},{"issue":"1","key":"2024052113000625000_2024.05.14.594201v1.54","first-page":"99","article-title":"MAGE-A and NY-ESO-1 expression in cervical cancer: prognostic factors and effects of chemotherapy","volume":"198","year":"2008","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"2024052113000625000_2024.05.14.594201v1.55","first-page":"329","article-title":"Melanoma-associated antigen-A1 expression predicts resistance to docetaxel and paclitaxel in advanced and recurrent gastric cancer","volume":"18","year":"2007","journal-title":"Oncol Rep"},{"issue":"5","key":"2024052113000625000_2024.05.14.594201v1.56","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00262-019-02316-w","article-title":"Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma","volume":"68","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"2024052113000625000_2024.05.14.594201v1.57","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25607"},{"key":"2024052113000625000_2024.05.14.594201v1.58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36400-8"},{"key":"2024052113000625000_2024.05.14.594201v1.59","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0169-x"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.05.14.594201","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:27:11Z","timestamp":1768458431000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.1101\/2024.05.14.594201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":59,"URL":"https:\/\/doi.org\/10.1101\/2024.05.14.594201","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1186\/s40478-025-02055-3","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2024,5,17]]},"subtype":"preprint"}}